Ozempic maker launches cheaper copy in Africa’s largest pharma market after court blocks unregistered Ozempic copies

Novo Nordisk is launching a cheaper authorised version of its blockbuster diabetes drug Ozempic in South Africa, intensifying its fight against unregulated compounded medicines, lower-cost generics and Eli Lilly’s fast-growing Mounjaro.